A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (Enstilar®) in the management of psoriasis with scalp involvement

Q2 Pharmacology, Toxicology and Pharmaceutics

Drugs in Context Pub Date : 2024-05-15 DOI:10.7573/dic.2024-1-6

Petra Staubach, Andreas Körber, Ralph M Trüeb, Caroline Mann, Ralph von Kiedrowski

{"title":"A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (Enstilar®) in the management of psoriasis with scalp involvement","authors":"Petra Staubach, Andreas Körber, Ralph M Trüeb, Caroline Mann, Ralph von Kiedrowski","doi":"10.7573/dic.2024-1-6","DOIUrl":null,"url":null,"abstract":"The scalp is the most common site affected in patients with psoriasis with up to 80% of these patients having some degree of scalp involvement. In this narrative review, we evaluate available data on the use of an innovative aerosol foam formulation of calcipotriol plus betamethasone dipropionate (Cal/BD) to treat patients with psoriasis and scalp involvement. The full PubMed database was searched using the terms “cal-cipotriol”, “betamethasone dipropionate” and “aerosol foam”, and all articles relating to “psoriasis with scalp involvement” were retrieved and used in the preparation of this review. The evidence supporting the clinical effectiveness, tolerability and impact on health outcomes of Cal/BD aerosol foam in patients with scalp psoriasis was obtained from a phase II clinical trial and real-world evidence data from a non-interventional study as well as from two case series. The findings from these studies show that Cal/BD aerosol foam is rapidly effective, improves skin condition, alleviates symptoms such as itch, and has a positive impact on patient quality of life. These attributes address several unmet needs for patients with psoriasis with scalp involvement and have the potential to improve individual adherence to treatment","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"72 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2024-1-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

The scalp is the most common site affected in patients with psoriasis with up to 80% of these patients having some degree of scalp involvement. In this narrative review, we evaluate available data on the use of an innovative aerosol foam formulation of calcipotriol plus betamethasone dipropionate (Cal/BD) to treat patients with psoriasis and scalp involvement. The full PubMed database was searched using the terms “cal-cipotriol”, “betamethasone dipropionate” and “aerosol foam”, and all articles relating to “psoriasis with scalp involvement” were retrieved and used in the preparation of this review. The evidence supporting the clinical effectiveness, tolerability and impact on health outcomes of Cal/BD aerosol foam in patients with scalp psoriasis was obtained from a phase II clinical trial and real-world evidence data from a non-interventional study as well as from two case series. The findings from these studies show that Cal/BD aerosol foam is rapidly effective, improves skin condition, alleviates symptoms such as itch, and has a positive impact on patient quality of life. These attributes address several unmet needs for patients with psoriasis with scalp involvement and have the potential to improve individual adherence to treatment

查看原文本刊更多论文

固定复方钙泊三醇/倍他米松气雾剂泡沫（Enstilar®）治疗头皮受累银屑病的叙述性综述

头皮是银屑病患者最常见的患病部位，高达 80% 的银屑病患者头皮都受到一定程度的影响。在这篇叙述性综述中，我们评估了使用钙泊三醇加二丙酸倍他米松创新气雾剂泡沫配方（Cal/BD）治疗银屑病头皮受累患者的现有数据。我们使用 "钙泊三醇"、"倍他米松二丙酸酯 "和 "气雾剂泡沫 "等词在整个 PubMed 数据库中进行了搜索，并检索了所有与 "头皮受累的银屑病 "相关的文章，并将其用于编写本综述。支持头皮银屑病患者使用 Cal/BD 气雾剂泡沫的临床有效性、耐受性和对健康结果的影响的证据来自一项 II 期临床试验、一项非干预性研究中的真实世界证据数据以及两个病例系列。这些研究结果表明，Cal/BD 气雾剂泡沫能迅速见效，改善皮肤状况，减轻瘙痒等症状，并对患者的生活质量产生积极影响。这些特性满足了头皮受累银屑病患者的一些尚未满足的需求，并有可能改善个人坚持治疗的情况

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs in Context Medicine-Medicine (all)

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.